A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

18F-PSMA (n=3) and 68Ga-PSMA (n=3)

Inclusion criteria:

* Persons \>18 yo with suspected prostate cancer metastasis
* Prior imaging study (CT, and/or MRI and/or Bone scan and/or Fluciclovine scan) suspicious for metastatic disease, obtained within 4 months from the research scan date.

  68Ga DOTATATE (n=3) or 64Cu-DOTATATE (n=3)

Inclusion Criteria:

* Persons \> 18 yo suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors (NETs)
* Prior DOTATATE PET/CT scan suspicious for tumor obtained not earlier than 4 months from the research scan date.

Exclusion Criteria:

• Recent administration of long-acting somatostatin analogs

Exclusion Criteria for all participants:

* Adults unable to consent
* Pregnant/lactating persons
* Prisoners
* Unable to lie supine for up to 90 minutes at different timepoints in the PET scanner
* Uncontrolled claustrophobia
* Any significant medical condition that in the opinion of the investigator would prevent the participant from participating and/or adhering to study related procedures or interfere with participant safety